The Centers for Disease Control and Prevention (CDC) measures the amounts of just 300 chemicals in only 2,500 persons every two years. Those studies show that many of those chemicals are within our bodies at high levels. Those CDC processes are very costly and not available to everyday people. XCellAssay has created an affordable technology that uses cell lines engineered to alert you which chemical types are in your bodies at levels that may affect your health. XCellAssay also seeks to compare your measurements with the experiences and measurements of millions of other users, to provide recommendations to reverse any chemical disruption of your health.
Fred Schaufele, PhD
CEO and Director of Scientific Operations
Irina Krylova, PhD
Director of Environmental Studies
HaiGuang Zhang, PhD
Director of Technology
Director of Consumer IT
XCellAssay announces renewal of its agreement for the right to negotiate an exclusive license with the UCSF Office of Innovation Ventures for the technology covered in US Patent #10,324,099 (Inventor, Dr. Fred Schaufele, co-Founder, XCellAssay). A prior freedom to operate analysis conducted with the Startup Legal Garage program of the University of California Hastings College of the Law indicated that no patents or patent applications were found at the time of the report that “appear to have issued claims or claims that are likely to issue that should be infringed by the XCA’s Product”.
XCellAssay Co-Founder and CEO Fred Schaufele discusses our technology with the long-running Anti-Doping PodCast. The conversation focuses on lowering the high rates of abuse of anabolic steroids by amateur athletes, particularly youths, as performance enhancing drugs (PEDs). https://cleancompetition.org/2022/03/01/73-innovative-approaches-for-detecting-anabolic-androgenic-steroid-abuse-fred-schaufele-phd/
XCellAssay announces the continuation of funding by the Partnership for Clean Competition (PCC) for the development of our technology for identifying persons exposed to known or unknown androgens or anabolic androgenic steroids. The PCC, which was founded by the U.S. Olympic & Paralympic Committee, the US Anti-Doping Agency, the National Football League and Major League Baseball, has awarded three research studies by Dr. Schaufele to develop the measurement capability as part of the PCC’s mission “to help generate the world’s most influential, effective and coveted methods and resources for detecting and deterring the use of performance enhancing substances by all athletes in all sports at all levels”.
Abstracts of two XCellAssay studies, originally scheduled for presentation at the 2020 meeting of The Endocrine Society (cancelled due to the COVID-19 response), now are available at the Journal of the Endocrine Society:
https://academic.oup.com/jes/article/4/Supplement_1/SAT-748/5833501 and https://academic.oup.com/jes/article/4/Supplement_1/SUN-LB138/5832320